New study tests best way to cycle osteoporosis drugs for stronger bones

NCT ID NCT06938152

Recruiting now Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two treatment schedules for postmenopausal women with severe osteoporosis. One group gets romosozumab for 12 months then denosumab for 12 months. The other group cycles between the two drugs every 6 months for 2 years. Researchers will measure bone density and pain to see which schedule works better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Romosozumab and Denosumab (drugs given in sequence or cycles)
What this could lead to: If successful, this could identify a more effective dosing schedule for these osteoporosis drugs, potentially leading to better bone density gains and fewer fractures.
What could go wrong: This is a small, early-phase 4 trial with only 70 participants, so results may not apply to all patients. The drugs have known risks like jaw problems or unusual thigh fractures, and cycling may not prove better than standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS OSTEOPOROSIS, POSTMENOPAUSAL

Contacts and locations

Locations

National Taiwan University Hospital
RECRUITING

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.